


Dx&Vx

IR Letter

(Sep. 2024)



Dx&Vx Business Roadmap



Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

Genomic Diagnostics
In Vitro Diagnostics and CDMO
Genomics CRO
Companion Diagnostic Services (CliDex)



Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

Microbiome-based Therapeutic Adjuncts
Nutrition Products
Domestic and International CSO
Functional Skincare/Personal Hygiene Products



Drug Development

Our affiliate, Oxford Vacmedix, is preparing to initiate phase 1b clinical trials both domestically and internationally for its cancer vaccine, OVM-200, and our subsidiary Avixgen is about to start phase 2 trials for a dry eye treatment. Additionally, we have a pipeline of in-house developed drugs including microbiome-based therapies, mRNA cancer vaccines, oncology antibodies, and oral obesity treatments.

Microbiome-based Drug Development
ROP and mRNA Cancer Vaccines
Cancer Antibody Drugs, Synthetic Organic Drugs
Ophthalmic Disease Treatment Drugs



Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

K-hub
Telemedicine Services
AI-based Drug Development Platform
Smart Diagnostic Devices

Performance Summary for August 2024

-  Patent application for oral obesity treatment candidate / Anti-obesity strain patent application / mRNA anticancer vaccine candidate patent application / Recruitment of excellent R&D personnel
-  Signing \$7.7 Million for Export of its Brand Healthcare Products to China
-  Securing additional regions and customers for overseas expansion of dielectric analysis services
-  Strengthen competitiveness in digital healthcare



Drug Development

Patent application for oral obesity treatment candidate

Our company has recently completed the patent applications for two oral obesity treatment drugs based on the low molecular weight GLP-1 receptor agonist (GLP-1RA). The first patent was filed early on August 26, which has accelerated our drug development process and is addressing the inconveniences and high production costs associated with injectable treatments. The second patent was filed on September 2, and both patents are expected to show differentiated effects through various compound structures and mechanisms of action. We are working with a development team, which includes former staff from Hanmi Pharmaceuticals and Daewoong Pharmaceutical, to provide customized treatments tailored to individual patient characteristics. We plan to accelerate development through various strategic collaborations. Additionally, we are seeking collaborations with numerous overseas pharmaceutical companies to expedite global clinical trials and market entry, and we are actively working on the commercialization stage of the new drug through early licensing out, global joint clinical trials, and research funding investments.

Patent application for Anti-obesity Strain

Our Microbiome Research Laboratory has discovered and completed the patent application for an anti-obesity microbial strain (DX2034) that reduces body fat. This strain is effective in early-stage obesity, and we are expanding our pipeline related to obesity and metabolic disorders in conjunction with our GLP-1 oral obesity treatments. Furthermore, we plan to further develop this anti-obesity strain to address obesity, a major concern in modern society, and expand our pipeline for obesity and metabolic diseases. We also intend to set up a mass production system after securing ingredients recognized for their functionality through subsequent human trials.

mRNA anticancer vaccine candidate patent application to be filed

We plan to file a patent this year for a prototype mRNA anticancer vaccine candidate that we are developing. Our mRNA anticancer vaccine targets intractable cancers such as triple-negative breast cancer, and melanoma has already demonstrated its preclinical effectiveness. By applying AI-based mRNA vaccine structure design technology, the company plans to analyze the genetic differences between cancer cells and normal cells in cancer patients and develop a vaccine for novel antigens, a genetic mutation that only exists in cancer cells in specific cancer patients. We have already developed an mRNA platform in the meantime, working with Hanyang University to develop an SOP for the development of a personalized new antigen-based mRNA anticancer vaccine. We plan to quickly confirm the anticancer effectiveness of the independently designed mRNA anticancer vaccine candidate targeting intractable cancers, prepare for patent applications, and support the government's mRNA vaccine localization support project.

Recruitment of excellent R&D personnel

In order to accelerate the development of new drugs and add excellent pipelines, the company recently invited Dr. Nam-Joon Cho, a master scholar in infectious diseases and biomaterial medicine, as an advisor to the Americas business division and recruited Vice President Shim Sung-nyeo from Global Big Pharma as the head of the product development division. Dr. Nam-Joon Cho is a chair professor at Nanyang Technological University in Singapore and a project leader of the Center for the Development of New Antiviral Drugs for Pandemic Pathogens at Stanford University, funded by the National Institute of Infectious Diseases (NIAID). Vice President Shim Sung-nyeo is an expert with experience in pharmaceutical and biological companies at home and abroad, including Merck, GSK, and Samsung Biologics. Through the recruitment of such global pharmaceutical and biological talents, the company plans to come up with countermeasures against "disease X" that may arise newly such as vaccines and immunizations and infectious diseases, and strive to accelerate the development and early commercialization of the pipeline currently under development.



Consumer Healthcare

Sign contract worth \$7.7 million for its brand healthcare products in China

On August 30, 24, the company signed a \$7.74 million export contract for healthcare products with China's Hangzhou Guangxi Company. Through this export contract, we will supply microbiome-based treatment supplements and diet lactobacillus products jointly developed by the company with Coree Italy's AAT Research Institute. These products will be distributed online through China's Wu Chanjung Da Yunchang, one of 40 affiliates under the Chinese Wu Chanjung Da Group (annual sales of 108 trillion won), and it is known to have annual sales of 1.9 trillion won as a company specializing in premium health foods and household goods. Meanwhile, the company signed a \$4 million export supply contract with Vietnam's Opmei in June and is further discussing export consultations with healthcare distributors in many countries to develop its brand's overseas markets.



Medical Diagnostics

Genome Analysis Services to secure additional regions and customers overseas

The Company has signed a local market supply agreement for the dielectric analysis service "Genome Check" with the major pharmaceutical company Induer Medical in the Philippines. Induer Medical is a subsidiary of the Pharmwells Group and has networks in Asia, Europe, and the United States, including the Philippines. Through this agreement, we plan to expand cooperation with Induer Medical in the field of in vitro diagnostics and digital healthcare as well as dielectric analysis. Following Malaysia and Mongolia, the Company is actively exploring clients and entering the market quickly in Southeast Asian markets, including the Philippines. Through this, we expect to strengthen our leading position in the global precision medical market and increase sales and profitability.



Digital Healthcare

Strengthen competitiveness in digital healthcare_Building an AI-based digital healthcare system

To build an AI-based digital healthcare system, we have introduced Herings patent-only licenses and sublicensing rights. Herings is a company specializing in AI remote patient monitoring platform services, and is developing customized care solutions for cancer patients. This patent, which secures exclusive license, remotely accesses, controls, manages, and shares health care for the postoperative prognostic process of cancer patients and gastrectomy patients. Through this patent introduction, we plan to strengthen our position in the digital therapeutic market and promote the development of digital therapeutics necessary for postoperative prognostic management, presenting a new paradigm in patients' prognostic management systems.

Compliance Notice

This document is prepared solely for informational purposes to assist investors' understanding. It is based on data and information considered reliable, and has been diligently compiled; however, we do not guarantee its accuracy or completeness. Investment decisions should be made based on the investor's own judgment and responsibility. Under no circumstances can this material be used as legal evidence of liability for investment results.